Latest Recruitment News

Prescient Therapeutics has extended its Share Purchase Plan by three days after shareholders reported delays receiving application documents. The revised timetable places the offer’s results announcement just ahead of a planned briefing on the company’s PTX-100 development program.

Lithium Universe has secured selection for a proposed four-year Industry PhD project with Macquarie University and CSIRO to develop microwave-assisted recycling of end-of-life solar panels. The collaboration could strengthen the company’s technology pathway, but its grant, agreement and commercial outcomes remain unconfirmed.

Tivan has won approval to add 50 square kilometres to its Baucau copper-gold project in Timor-Leste, securing ground over a large magnetic anomaly. The expansion comes as the company acknowledges an executive chairman’s personal X post previewed an assay announcement before ASX release and was not authorised under its disclosure policy.

HiTech Group Australia has completed its acquisition of selected Hudson Global Resources assets, expanding its workforce solutions platform across five Australian jurisdictions. The deal lowers the upfront price but leaves some customer, government panel and contractor novations unfinished during the transition.

Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.

Pathkey.AI has appointed Nanyang Technological University chip design and AI specialist Professor Anupam Chattopadhyay to the new Advisory Board supporting Chipforge. The appointment adds technical and commercialisation experience as the AI-native semiconductor platform moves from development towards a product launch, although no launch date or commercial contract was disclosed.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Prescient Therapeutics has given shareholders another week to participate in its A$7 million share purchase plan, citing delayed documentation and requests for more time. The capital raising is intended to fund PTX-100 through a planned December 2026 Dose Optimisation Committee meeting.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

HiTech Group has formalised its acquisition of Hudson Global Resources' Australian assets with a $7 million upfront price, plus up to $3 million in deferred payments tied to future cash flow. Completion is targeted for 11 September 2026, pending final conditions.

Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.

EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.